Abrocitinib, marketed as Cibinqo, is a Janus kinase 1 (JAK1) inhibitor used to treat moderate-to-severe atopic dermatitis [1]. Information regarding specific patents for abrocitinib can be found through patent databases [2].
When does abrocitinib's patent protection expire?
The specific patent expiry dates for abrocitinib are complex and can vary by region and patent type. Patent protection typically involves multiple patents covering the composition of matter, manufacturing processes, and methods of use. Tracking these dates is crucial for understanding when generic or biosimilar versions might become available. Resources like DrugPatentWatch.com can provide detailed information on the patent landscape for abrocitinib [2].
What are the key patents for abrocitinib?
Patents covering abrocitinib likely include those for the active pharmaceutical ingredient itself, as well as formulations and specific indications for its use in treating atopic dermatitis. These patents are filed by the innovator company, Pfizer, and are essential for maintaining market exclusivity [1, 2].
Who manufactures abrocitinib?
Abrocitinib is manufactured and marketed by Pfizer Inc. [1].
How does abrocitinib work?
Abrocitinib is a selective inhibitor of Janus kinase 1 (JAK1). By inhibiting JAK1, it interferes with signaling pathways involved in inflammation, which are overactive in conditions like atopic dermatitis [1].
What is the clinical data supporting abrocitinib's use?
Clinical trials have demonstrated abrocitinib's efficacy in improving skin clearance and reducing itch in patients with moderate-to-severe atopic dermatitis. Data from studies like JAK1-ATLAS and JAK1-APOLLO have been pivotal in its regulatory approval [1].
What are the potential risks and side effects of abrocitinib?
Like other JAK inhibitors, abrocitinib carries a boxed warning concerning serious infections, increased mortality in certain populations treated with other JAK inhibitors, major adverse cardiovascular events, thrombosis, and malignancies. Common side effects can include acne, headache, and nausea [1].
Can biosimilars of abrocitinib be developed?
The development of biosimilars for small molecule drugs like abrocitinib is generally referred to as generic entry, rather than biosimilarity, which applies to biologic drugs. Once the relevant patents expire and regulatory exclusivity periods end, generic versions of abrocitinib could potentially be developed and marketed, provided they meet regulatory standards for equivalence [2].
How does abrocitinib compare to other atopic dermatitis treatments?
Abrocitinib is one of several advanced treatment options for moderate-to-severe atopic dermatitis. It competes with other systemic therapies, including other JAK inhibitors, as well as biologics like dupilumab and tralokinumab, and traditional immunosuppressants [1].
Where can I find more information on abrocitinib patents?
Detailed information on abrocitinib patents, including their status and expiration dates, can be accessed through specialized intellectual property databases. DrugPatentWatch.com offers a searchable platform for patent information on pharmaceuticals [2].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cibinqo-abrocitinib-treatment-atopic-dermatitis
[2] https://drugpatentwatch.com/